Aeronid 0.5 mg/2 ml is an inhaled corticosteroid formulation designed for the maintenance and prophylactic treatment of asthma in both adult and pediatric patients aged 6 years and above. It contains budesonide, a potent anti-inflammatory corticosteroid that helps control chronic airway inflammation, reduce asthma symptoms, and prevent exacerbations. Aeronid 0.5 mg/2 ml is intended for regular use and is not suitable for the relief of acute bronchospasm or asthma attacks.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Nasal Decongestants & Other Nasal Preparations, Respiratory Corticosteroids

Indications

Aeronid 0.5 mg/2 ml is indicated for:

• Maintenance treatment of asthma as prophylactic therapy in adults and children aged 6 years or older

• Asthma patients requiring oral corticosteroid therapy, where long-term use of Aeronid may allow dose reduction or discontinuation of systemic corticosteroids

This medication is not indicated for the treatment of acute asthma symptoms or status asthmaticus.

Pharmacology and Mode of Action

Aeronid 0.5 mg/2 ml contains budesonide, a corticosteroid with strong glucocorticoid activity and weak mineralocorticoid activity. It exerts its therapeutic effect by inhibiting inflammatory responses in the airways. Budesonide suppresses the activity of multiple inflammatory cells such as mast cells, eosinophils, neutrophils, macrophages, and lymphocytes, and inhibits the release of inflammatory mediators including histamine, leukotrienes, eicosanoids, and cytokines. These actions reduce airway inflammation, improve lung function, and enhance long-term asthma control.

Dosage and Administration

Aeronid 0.5 mg/2 ml should be administered via oral inhalation in patients aged 6 years and above. Dosage should be individualized according to disease severity and previous asthma therapy.

Adults

• Bronchodilators alone:

  • Starting dose: 200–400 mcg twice daily

  • Maximum dose: 400 mcg twice daily

• Inhaled corticosteroids:

  • Starting dose: 200–400 mcg twice daily

  • Maximum dose: 800 mcg twice daily

• Oral corticosteroids:

  • Starting dose: 400–800 mcg twice daily

  • Maximum dose: 800 mcg twice daily

Children

• Bronchodilators alone:

  • Starting dose: 200 mcg twice daily

  • Maximum dose: 400 mcg twice daily

• Inhaled corticosteroids:

  • Starting dose: 200–400 mcg twice daily

  • Maximum dose: 400 mcg twice daily

• Oral corticosteroids:

  • Maximum recommended dose: 400 mcg twice daily

In patients with well-controlled mild to moderate asthma, once-daily dosing of 200–400 mcg may be considered. If asthma control is inadequate, the dose may be increased or divided. For patients transitioning from long-term oral corticosteroids, gradual tapering is recommended under close medical supervision.

Contraindications

• Primary treatment of status asthmaticus or acute asthma episodes requiring intensive intervention

• Known hypersensitivity to budesonide or any component of the formulation

Side Effects

Commonly reported adverse effects include headache, flu-like symptoms, fever, back pain, asthenia, respiratory tract infections, pharyngitis, sinusitis, rhinitis, cough, and voice changes. Gastrointestinal effects may include oral candidiasis, nausea, vomiting, abdominal pain, dyspepsia, and dry mouth. Other possible effects include weight gain, myalgia, arthralgia, insomnia, skin bruising, taste disturbance, and, rarely, infections related to immune suppression.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

Care should be taken during withdrawal from systemic corticosteroids, as patients may experience symptoms such as joint pain, muscle pain, fatigue, or depression. Although Aeronid 0.5 mg/2 ml reduces the risk of hypothalamic-pituitary-adrenal (HPA) axis suppression compared to oral corticosteroids, systemic effects may still occur at high doses. Patients should be maintained on the lowest effective dose and monitored regularly, especially during periods of stress or severe asthma exacerbations.

Use in Special Populations

Clinical studies in pediatric patients have shown no significant differences in safety or adverse event profiles compared to adults when used at recommended doses.

Storage Conditions

Store below 30°C, protected from light and moisture. Keep out of the reach of children.